A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB
A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
California
-
Redwood City, California, United States, 94063
- Stanford University
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01605
- University of Massachusetts Medical School
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Willing and able to give consent/assent;
- If under the age of 18, guardian(s) is/are willing and able to give consent;
- Prior study treatment with EB-101.
Exclusion Criteria:
- Inability to properly follow protocol as determined by the Principal Investigator
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Long-Term Extension
This study will follow one group of participants who were enrolled in a previous EB-101 study.
|
This is non-interventional and follows patients treated with EB-101
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Wound Closure
Time Frame: 5 years
|
Proportion of RDEB wounds with healing ≥50%, ≥75%, and 100% at all clinic visits up to Month 54 as determined by direct investigator assessment.
|
5 years
|
|
Wound Infection and Adverse Events
Time Frame: 5 years
|
The number of participants and wounds that have an infection or any related adverse event.
|
5 years
|
|
The number of treatment-emergent adverse events.
Time Frame: 5 years
|
The number of treatment-emergent adverse events.
|
5 years
|
|
Serious Adverse Events
Time Frame: 5 years
|
The number of participants and wounds that result in hospitalization (serious adverse event [SAE]).
|
5 years
|
|
Incidence of squamous cell carcinoma.
Time Frame: 5 years
|
Incidence of squamous cell carcinoma.
|
5 years
|
|
Replication-competent retrovirus (RCR) status
Time Frame: 5 years
|
Replication-competent retrovirus (RCR) status
|
5 years
|
|
Pain Severity Scale (Wong-Baker FACES)
Time Frame: 5 years
|
Change in pain assessed by Wong-Baker FACES scale at all clinic visits up to Month 54.
The minimum score value is 0 and the maximum score value is 10, with the higher scores being the worse outcome.
|
5 years
|
|
Itch Severity Scale
Time Frame: 5 years
|
Longitudinal change of Itch severity scores assessed at all clinic visits up to Week 54.
The minimum score value is 0 and the maximum score value is 10, with the higher scores being the worse outcome.
|
5 years
|
|
Caregiver Global Impression of Change for Pain Scale
Time Frame: 5 years
|
Caregiver Global Impression of Change for Pain (CrGI-Pain) scores assessed at all clinic visits up to Month 54.
The minimum score value is 1 and the maximum score value is 7, with the higher scores being the worse outcome.
|
5 years
|
|
Zarit Burden Interview Scale
Time Frame: 5 years
|
Longitudinal change of Zarit Burden Interview Short Form (ZBI-12) for caregiver scores related to wound care, assessed at all clinic visits up to Month 54.
The minimum score value is 0 and the maximum score value is 4, with the higher scores being the worse outcome.
|
5 years
|
|
Quality of Life in Epidermolysis Bullosa
Time Frame: 5 years
|
Quality of Life in Epidermolysis Bullosa (QOLEB) responses will be assessed at all clinic visits up to Month 54.
|
5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Angela Iheanacho, MS, Abeona Therapeutics, Inc
- Study Director: Sarah Abdelwahab, MD, Abeona Therapeutics, Inc
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- EB-101-LT-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.